Viking Therapeutics is trading 4.78% down at $33.86 as investors digest its $500 million stock-and-convertible-notes financing.
- Announced September 24, the offering included 7,857,143 shares and $225 million of convertible notes; coverage linked its dilution impact to the recent selloff.
- Shares continued retreating as investors digested the raise. Broader markets were also lower on September 28 amid rising oil prices and Treasury yields, adding a cautious backdrop.